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Abstract
In utero exposure to tobacco products, whether maternal or environmental, have harmful effects on first neonatal
and later adult respiratory outcomes. These effects have been shown to persist across subsequent generations,
regardless of the offsprings’ smoking habits. Established epigenetic modifications induced by in utero exposure are
postulated as the mechanism underlying the inherited poor respiratory outcomes. As e-cigarette use is on the rise,
their potential to induce similar functional respiratory deficits underpinned by an alteration in the foetal epigenome
needs to be explored. This review will focus on the functional and epigenetic impact of in utero exposure to
maternal cigarette smoke, maternal environmental tobacco smoke, environmental tobacco smoke and e-cigarette
vapour on foetal respiratory outcomes.
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Background
Foetal lung organogenesis is an extensive and multi-stage
process, commencing with the development of the lung
bud by the 4th gestational week, with lobar and vascu-
larised subsegmental branching occurring by the 6th week
[1]. Genesis of conducting airways, with airway cartilage,
smooth muscle, mucous glands and epithelial cell differ-
entiation commences as early as gestational week 7 [1].
Completion of a full-term pregnancy allows for formation
of true alveoli and maturation of surfactant in Type II epi-
thelial cells [1, 2], allowing for healthy gas exchange. Upon
delivery, lung development will continue postnatally, with
significant alveolar growth occurring during the first 2
years of life [3] and into adolescence [4]. This protracted
period of development, commencing in utero and
continuing into adolescence, makes the pulmonary system
particularly vulnerable to environmental insults affecting
normal lung development. Harmful exposures during
development can alter the course of healthy lung
development and set the child on a trajectory making
them more vulnerable to disease [5–7].
Asthma and chronic obstructive pulmonary disease
(COPD) are diseases of the airway, wherein patients ex-
perience common symptoms such as shortness of
breath, cough and wheeze, and share some similar
pathological changes collectively termed airway remodel-
ling. What sets them apart at a functional level is the
age of onset of symptoms, etiological causes, progression
of the disease and response to existing therapeutics.
Asthma is a heterogenous disease experienced by 235
million people worldwide [8] and is the most prevalent
chronic disease in developed countries. Asthma typically
develops early in life with patients experiencing symp-
toms during an exacerbation episode known as an
‘asthma attack’, which typically responds well to bron-
chodilators and can be controlled using corticosteroids.
Overall, asthmatic mortality rates have fallen but deaths
during asthma attacks subsist, with higher prevalence in
the elderly [9]. Atopy is common in asthma, mediated by
CD4+ Th2 cells and infiltration of mast cells and eosino-
phils in the airway walls. Inflammation and increased
smooth muscle bulk comprise airway wall remodelling in
asthma, causing airway obstruction [9, 10].
* Correspondence: brian.oliver@uts.edu.au
1Respiratory Cellular and Molecular Biology, Woolcock Institute of Medical
Research, The University of Sydney, Sydney, Australia
2School of Life Sciences, University of Technology Sydney, Sydney, Australia
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zakarya et al. Clinical Epigenetics           (2019) 11:32 
https://doi.org/10.1186/s13148-019-0631-3
COPD is the fourth most common cause of death
worldwide with prevalence increasing in concert with
the ageing population [11, 12]. In contrast to the age of
onset in asthma, COPD—except anti-α-trypsin COPD—
develops later in life. COPD patients generally show a
limited response to corticosteroids and upon manifest-
ation of the disease, lung function progressively declines
until death or transplantation. Inflammation in small air-
way walls of COPD patients is mediated by CD8+ Tc1
cells, consists of neutrophils and macrophages [9, 10]
and is most prevalent in peripheral airways [13]. In con-
junction with small airway obstruction, COPD patients
may experience emphysema, which manifests as loss of
alveolar space. Pathologically, patients can be clustered
into predominantly experiencing either small airway ob-
struction or emphysematous destruction [9].
Both asthma and COPD have an inherited component,
but the aetiology and risk factors for the two are differ-
ent. Typically, asthma is an allergic disease and COPD is
the result of inhalation of noxious gases; however, there
is considerable overlap of the two diseases, and in some
cases, asthma and COPD can co-exist and asthma can
progress into COPD. The differences between COPD
and asthma are attributed to different gene environment
interactions and different genetic risk factors. Patho-
logically the two diseases are distinct, for example differ-
ing inflammatory profiles and sites of inflammation
within the airway wall [9, 14], but asthmatics and COPD
patients both experience obstruction of the airways. A
useful diagnostic tool for airway obstruction is spirom-
etry, wherein patients’ forced expiratory volume in 1 sec-
ond (FEV1) demonstrates how quickly a patient can
expel air from their lungs. A lower FEV1 indicates
greater airway obstruction. The main spirometric differ-
ence is that asthma has reversible airway obstruction,
but COPD has incomplete reversal of airway obstruc-
tion. However, spirometry alone cannot differentially
diagnose the two diseases. In severe forms of asthma, for
example asthma with fixed airflow limitation, lung physi-
ology can resemble COPD, and similarly patients with
COPD can be highly responsive to bronchodilators.
This review will focus on the epigenetic impact of spe-
cific environmental insults such as environmental to-
bacco smoke (ETS), maternal exposure to ETS (METS),
maternal use of tobacco smoke (MTS) and maternal
e-cigarette vapour (MEV) exposure on the offspring’s
lung development and function, with a focus on asthma
and COPD.
Epigenetics in asthma and COPD
Studies have shown that family history of COPD is a risk
factor for manifestation of the disease [15, 16]. Similarly,
siblings and first-degree relatives of asthmatics are often
affected with lower FEV1 [17, 18], thereby suggesting a
heritability factor in asthma and COPD. The absence of
a correlation between findings of a COPD or asthma
SNP in genome-wide associations studies (GWAS) sug-
gests that the hereditary effect is likely established at the
epigenomic level rather than genomic and might have
greater impact on gene expression in cells at the site of
disease [19].
Epigenome-wide association studies (EWAS) have
found that leukocytes from COPD patients have 349 dif-
ferentially methylated CpG sites compared to those from
non-COPD smokers [20]. A similar study using small
airway epithelial cells found 1260 differentially methyl-
ated CpGs related to COPD [21]. DNA methylation sta-
tus at the promoter of GATA4 measured in sputum
samples has been associated with impaired lung function
[22, 23] and health outcomes in COPD [22]. Whilst aug-
mented mRNA expression of DEFB1, a gene associated
with COPD [24], has been attributed to trimethylation
of H3K4 [25].
The balance of Type 1 helper T-cells (Th1) and Type
2 helper T-cells (Th2) is crucial in the development of
atopic asthma [26]. Epigenetic changes, such as methyla-
tion at the interferon-γ (Ifn-γ) promoter, have been asso-
ciated with skewing naïve T-cells towards an atopic Th2
phenotype [27]. Murine models of asthma have shown
that genetic components involved in transcription of
Th2 cytokine, IL-13, are regulated by DNA methylation
and miRNAs with predicted targets essential in allergic
airways disease [28].
The innate immune system is naturally plastic and
therefore particularly vulnerable to epigenetic modifica-
tions. Further, aberrant accumulation of leukocytes such
as neutrophils and eosinophils has been implicated in
both asthma and COPD [9] suggesting that dysregulated
epigenetic modulation of these cells could contribute to
disease pathology. A study using bronchoalveolar lavage
(BAL) macrophages from patients with COPD found
lower expression of HDAC2 mRNA and showed de-
creased histone deacetylase (HDAC) activity in smokers
that correlated with significantly higher levels of IL-1β
and TNFα [29]. There was an altered ability of the BET
mimic JQ1 to suppress specific cytokine gene expression in
COPD BAL macrophages [30] which together demonstrate
that epigenetic changes contribute to disease pathology.
For a comprehensive review on epigenetics in airways dis-
ease, it is recommended to read Durham et al [31].
Functional and epigenetic outcomes of maternal tobacco
smoke (MTS), maternal environmental tobacco smoke
(METS) and environmental tobacco smoke (ETS) exposure
Although awareness campaigns have led to a general de-
cline in smoking rates across the world, MTS is an on-
going issue [32, 33]. Rates vary widely between
countries, with some EU nations as low as 5% (Sweden,
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Austria, Switzerland) and others as high as 40% (Greece)
[34–36]; in the US 10.7% of mothers smoke during the
last trimester [33]. Together, these data demonstrate that
maternal smoking is a worldwide problem. Maternal to-
bacco use is not the only means of foetal tobacco expos-
ure with epidemiological studies reporting up to 50% of
women in China are exposed to ETS while pregnant
[37]. Further, it is estimated that the aforementioned MTS
and ETS exposure rates do not accurately reflect the true
extent of the problem as smoking parents have been
shown to falsely report their habit [38] and 50% of smokers
continue to smoke throughout their pregnancy [39].
Studies have quantified levels of cotinine in amniotic
fluid of pregnant smokers and blood from neonates ex-
posed to MTS [40, 41], confirming that nicotine can
cross the placenta in utero [40, 42]. An investigation of
nicotine exposure in neonates found cotinine levels
comparable to that observed in active smoking adults
[43, 44]. It is presumed that the antenatally exposed infant
will continue to be exposed to nicotine postnatally through
ETS exposure and breast milk [45, 46] with 40% of chil-
dren reportedly exposed to ETS [47]. Studies have found a
positive correlation between concentration of nicotine in
maternal blood and foetal growth retardation [48].
Harmful effects of MTS on lung development have
been detected early on with a slower pace of septal
growth, subsequent alveolarisation [49, 50], and foetal
lung size of MTS-exposed babies reduced by the 33rd
gestational week [51]. Mothers continuing to smoke dur-
ing pregnancy have a 25% higher likelihood of preterm
labour [52], causing a disruption of healthy lung organo-
genesis leading to aberrant development [53].
MTS exposure also increases risk of asthma [54, 55]
and wheeze [54, 56] in the offspring, with paternal
smoking being an additive risk [55]. Negative respiratory
outcomes for infants exposed to MTS include irregular
tidal breathing patterns, decreased passive respiratory
compliance, and decreased forced expiratory flows [51, 57],
with decreased lung function persisting into adolescence
[55, 57] and early adulthood [58, 59]. Paternal smoking
during puberty, when spermatogonia are developing,
increases the risk for asthma in offspring [60], thereby
demonstrating that parental smoking behaviour has a
long-term effect on respiratory outcomes in the offspring.
Exposure to ETS significantly decreases FEV1 [61, 62]
and is an independent risk factor for developing asthma
[63]. Asthmatic children exposed to ETS have more se-
vere asthma [64] and frequent exacerbations requiring
hospitalisation [65] and tend to have slower recoveries
than those not exposed to ETS [66]. Indeed, urinary co-
tinine levels positively correlate with ETS exposure levels
and the severity of asthma exacerbations [67] and higher
blood cotinine concentrations are linked to bronchial
hyperresponsiveness [68]. Removing ETS from an
asthmatic child’s environment has shown positive health
outcomes by lessening symptoms [69]. Women exposed
to ETS during childhood were twice as likely to develop
COPD whilst men showed a slightly increased risk of re-
duced lung function when compared with those not ex-
posed to ETS during childhood [70]. Childhood ETS
exposure combined with previous MTS exposure has
been shown to have compounding effects that leave the
offspring more vulnerable to harmful effects of active
smoking and decline in lung function [58, 71]. The effect
of MTS and ETS on COPD patients’ outcomes persists
long into their lives, with adult patients of smoking
mothers having significantly lower FEV1 than those of
non-smoking mothers [72].
Investigations into epigenetic aberrations in human
airway cells exposed to tobacco smoke found small air-
way epithelial cells experience dose-dependent changes
in histone acetylation and methylation, alongside de-
creased expression of DNA methyltransferases (DNMT)
[73]. Tobacco smoke-exposed H292 cells, derived from
human lung epithelia, showed augmented expression of
genes for enzymes involved with chromatin modifica-
tions, such as the histone deacetylase (HDAC), HDAC2,
and the histone acetyltransferase (HAT), Myst4, within
60min of exposure to tobacco smoke extract with ex-
pression of other HATs and HDACs upregulated at the
24-h time point [74]. Exposure of human bronchial epi-
thelial cells to the vapour phase of tobacco smoke, rather
than a tobacco smoke extract, found that tobacco smoke
induces acetylation at H3K27 and demonstrate that
these changes have a downstream effect on transcription
of genes related to stress responses [75].
COPD is a known risk factor for lung cancer and the
latter is also associated with an altered epigenome, and
several specific changes in miRNA expression, histone
modifications and DNA methylation profiles have been
reported in lung cancer and even proposed as bio-
markers of disease [76]. For example, the methylation sta-
tus of PGAM5 in human sperm cells is altered by
cigarette smoking which affects its expression [77].
PGAM5 expression was dysregulated in epithelial cells
and specific macrophage subtypes of COPD patients with
lung cancer with the latter associated with mortality [78].
Epidemiological evidence supports the notion that the
effects of MTS are heritable with further generations con-
tinuing to manifest poor respiratory outcomes. Grandma-
ternal smoking has been shown to affect the grandchild’s
lung development [60, 79] and increase the risk of asthma
independent of maternal smoking [80–82]. Furthermore,
MTS exposure experienced by the father in utero has been
shown to affect the respiratory outcome of his daughter,
independent of his smoking habits [83]. Murine models
confirm the direct effects of MTS on the offspring with in
utero smoke exposure decreasing lung volume [84, 85]
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and increasing airway resistance [85] and provide insights
into the mechanisms underlying these changes. The devel-
opmental differences are evident in MTS-exposed mice
offspring with significantly lower lung weights [86] and in-
creased ASM layer thickness and collagen deposition
upon allergen challenge with HDM compared to those ex-
posed to ambient air [87]. An intergenerational murine
model demonstrates that METS exposure lead to in-
creases in airway hyperactivity, airway resistance and de-
creases in lung compliance in offspring, which was then
passed down to the next generation in the absence of
METS exposure [88]. Similarly, allergen challenge elicited
an ameliorated atopic response demonstrated by eosino-
philia and significantly higher IL-13 levels in two subse-
quent generations when compared to the progeny of
ambient air exposed animals [88]; METS exposure and al-
lergen challenge were shown to deregulate miR-130,
miR-16 and miR-221 exposure and are postulated as the
epigenetic mechanism modulating the augmented IL-13
response induced by METS exposure [88].
Cigarette smoke constituents have been detected in
both the placenta and cord blood [43, 44] of newborns
and MTS exposure has been shown to cause changes in
global DNA methylation [89–93] and alter miRNA levels
in germline cells [94]. Hence, there is no question that
MTS exposure alters the foetal epigenome. The effects
of aberrant DNA methylation patterns in cord blood and
placenta are demonstrated by tissue-specific DNA
methylome analyses showing that MTS can induce spe-
cific changes to DNA methylation within the placenta in
genes crucial to foetal growth and development [92, 95].
Further, blood DNA methylation changes have been as-
sociated with lower FEV1 [96] and have been shown to
persist into childhood and adolescence [90, 97–101],
demonstrating that epigenetic modulations induced by
MTS have long-lasting effects on offspring’s lung func-
tion (Table 1). Various studies have shown that DNA
methylation changes caused by MTS occur at loci spe-
cific to established outcomes of maternal smoking such
as reduced foetal growth and wheeze [102, 103].
EWAS findings have shown MTS induced altered
methylation of DPP10 [104], a candidate gene identified
in GWASs [105, 106], in human foetal lung tissue.
Genes playing a role in attenuating the harmful effects
of tobacco smoke and its toxic constituents, such as
CYP1A1 [91] and AHRR [107], are modulated by DNA
methylation and have been shown to be altered by MTS
exposure. Immune cells from active smoking adults and
cord blood from neonates exposed to MTS both show dif-
ferential methylation of CYP1A1 and AHRR promoter re-
gions compared to non-smoke-exposed subjects [91, 108].
MTS exposure has been shown to cause demethylation of
the promoter region for receptor of insulin-like growth
factor 1 (Igf1R) in the murine lung [109] and methylation
of insulin-like growth factor 2 (Igf2) in human cord blood
[110], which both play an important role in lung develop-
ment and can contribute to asthma later in life. Interest-
ingly, the differentially methylated regions in Igf1R and
Igf2 induced by MTS have been shown to be sex
dependent, with the former only evident in females and
the latter males [109, 110]. Taken together with studies
showing MTS exposure affecting organs differently [111],
the findings fortify the requirement for specificity in epi-
genetic investigations as stimuli causing demethylation in
one organ or gender can have inverse effects in another.
Further investigations have shown that MTS exposure
dysregulated 133 miRNAs expressed in foetal murine
lungs, some of which played a role in transcription of
Igf1 which was significantly increased in female offspring
[86]. The authors validated these findings in humans by
showing increased Igf1 mRNA expressed from leuko-
cytes of school-aged children exposed to MTS [86],
demonstrating that the mechanism is conserved between
species and persists beyond infancy. METS alters lung
structure [112] and lowers birth weight in murine
models of exposure [88, 113]. Upon allergen challenge,
METS-exposed murine offspring express significantly
higher levels of Th2 cytokines in BAL fluid and lung,
lung eosinophilia and airway hyperreactivity when com-
pared to offspring exposed to ambient air antenatally
[114, 115] which corresponds with strong hypomethyla-
tion at the IL4 and IL13 promoters [114]. Augmented
expression of IL-13 in airways of METS-exposed murine
Table 1 Summary of respiratory function-specific epigenetic
changes in the offspring categorised by exposure
Epigenetic changes induced by MTS
Altered global DNA methylation Whole blood, cord blood, placenta
[89–93]




Placenta, cord WBC, cord blood,
murine lung [95, 102, 103, 109, 110]




detoxification of tobacco smoke,
CYP1A1 and AHRR, show altered
methylation
Placenta, cord blood [91, 107]
miRNA involved in transcription
of Igf1 upregulated
Murine lung [86]
Epigenetic changes induced by METS





correlate with Th2 cytokines
Murine lung [118]
Epigenetic changes induced by MEV
Global DNA hypermethylation Murine lung [130]
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offspring correspond with demethylation at the IL13
promoter [116] demonstrating alterations to DNA
methylation induced by METS exposure contribute to
pathology in allergic asthma. Specific miRNAs are impli-
cated as regulators of the Th1/Th2 balance with ablation
of miR-21 expression significantly augmenting expres-
sion of Th1 cytokine IFNγ and ameliorating expression
of Th2 cytokine, IL-4 [117] in mice (Fig. 1). A study of
allergen-challenged mice exposed to METS found a
strong correlation between miR-155-5p, miR-21-3p and
miR-18a-5p and expression of Th2 cytokines in BAL
[118], implicating miRNAs in the modulation of
METS-induced atopy in offspring. These findings are
compelling when conjoined with the previously dis-
cussed study by Singh et al. [88] implicating miRNAs in
METS-induced augmented IL-13 production.
Functional and Epigenetic effects of MEV exposure
The negative health impacts of cigarette smoking are
well documented and agreed upon. As cigarette con-
sumption declines, an opening in the market has
formed. In response, established tobacco companies and
entrepreneurs alike have flooded the market with new
nicotine delivery devices. The most successful thus far
being the e-cigarette. Briefly, an e-cigarette is a
hand-held device comprised of a reservoir for an “e-li-
quid” and a heating element connected to a battery.
Upon use, the e-liquid passes through the heating elem-
ent, forming an “e-vapour” to be inhaled by the user.
Unlike a cigarette, there is no combustion in an
e-cigarette and it is subsequently marketed as a “health-
ier” alternative to cigarette smoking. However, the dec-
laration of healthiness is premature as the effects of
long-term e-cigarette use and indirect exposure to
e-vapour remain to be elucidated. The illusion of a
healthier alternative leaves the population at risk of en-
during damaging effects with at-risk groups being the
most vulnerable. It has been reported that pregnant
women have started to use e-cigarettes during pregnancy
at increasing rates [119].
The basic composition of an e-liquid is a mixture of
propylene glycol, glycerol and flavourings, which may
Fig. 1 Effect of IL-4 and IL-13 promoter region hypomethylation. a Methylation (Me) inhibits binding of RNA Polymerase II (RNA Pol II) to gene
promoter region, thereby suppressing gene transcription. b METS exposure demethylates IL-4 and IL-13 promoter region in offspring [114, 116],
allowing for RNA Pol II to commence mRNA transcription, leading to IL-4 and IL-13 protein translation; therein contributing to pathological changes in
the airway wall leading to goblet cell hyperplasia, increased mucin stores, promotion of IgE production, and accumulation of eosinophils, mast cells
and basophils. Mast cells and basophils further produce Th2 cytokines IL-5 and IL-13, further perpetuating the airway inflammation
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include nicotine but some e-liquids contain no nicotine
[120]. Notwithstanding coming under the jurisdiction of
the EU Tobacco Products Directive in May 2016,
e-liquid compositions continue to vary widely, and stud-
ies have identified discrepancies in actual versus re-
ported nicotine concentrations [121, 122]. Independent
analyses have detected harmful compounds such as
phthalates, diacetyl and acrolein in e-liquids [122–124].
Whilst indoor air quality studies have found that levels
of aerosolised polycyclic aromatic hydrocarbons (PAHs),
formaldehyde, acetaldehyde, acrolein and particulate
matter ≤ 2.5μm [120, 122] are significantly increased
when e-cigarettes are used indoors.
As established, the ingredients in an e-liquid vary
widely, with some shown to be capable of epigenetic
modifications. An in vitro experiment using EA.hy926
cells found that DNMT3b transcript was decreased fol-
lowing acrolein exposure [125]. Maternal exposure to
benzylbutylphthalate (BBP) caused global DNA hyper-
methylation in CD4+ T cells of the exposed dam and to
a greater extent in her offspring in a murine model of
exposure [126]. This hypermethylation significantly cor-
related with attenuated expression of the GATA-3 re-
pressor zinc finger protein 1 (Zfpm1)—a gene that
represses GATA-3 mediated Th2 cell development—
thereby promoting the Th2 phenotype. The authors fur-
ther validated the link between maternal urinary BBP
metabolite levels and Zfpm1 in humans using whole
blood samples from 4-year-old children in the lifestyle
and environmental factors and their influence on new-
borns allergy (LINA) cohort. Although only trace levels
of BBP were detected in e-liquids compared to other
phthalates [123], it is of import to note that BBP shares
a common metabolite—mono-n-butyl phthalate
(MnBP)—with phthalates more abundant in e-liquids,
such as diethyl phthalate. Therefore, it is imperative to
elucidate whether BBP, MnBP, or other phthalate metabo-
lites induce specific epigenetic modifications. A significant
correlation between maternal urinary MnBP levels during
pregnancy and asthma symptoms in the child persisting
until at least 6 years of age has been reported [126].
Direct e-cigarette vapour exposure leads to impaired
innate immune responses in murine lungs [127], whilst
murine models of MEV exposure have shown inimical
effects of e-cigarette vapour on neonatal lung develop-
ment [128]. There is a current paucity of studies on the
impact of MEV exposure on the foetal epigenome but
those that have been published thus far demonstrate that
MEV exposure leads to epigenetic aberrations in the off-
spring. A murine model of MEV exposure with and
without nicotine on cognitive function found that expos-
ure to MEV without nicotine significantly increased glo-
bal DNA methylation in the offspring when compared to
ambient air-exposed offspring, whilst MEV with nicotine
did not [129]. The study further showed that DNMT3a
and DNMT3b mRNA were ameliorated by MEV without
nicotine. Furthermore, mRNA for genes involved in his-
tone modifications Carm1, Atf2, Aurka, Aurkb and
Aurkc were also augmented by MEV without nicotine
only. Thereby suggesting that e-cigarette vapour is cap-
able of epigenetic modulation in the offspring independ-
ent of nicotine.
An investigation into the impact of MEV exposure on
respiratory outcomes found that MEV exposure with
and without nicotine induced significant global DNA
hypermethylation in offsprings’ lungs compared to
air-exposed controls [130]. Interestingly, MEV without
nicotine elicited significantly greater DNA hypermethy-
lation compared to those induced by MEV with nicotine
with enhanced expression of the pro-inflammatory cyto-
kines IL-5, IL-13, TNF-α mRNA only seen in the lungs
of offspring exposed to MEV without nicotine [130].
The analysis of changes in global DNA methylation
patterns demonstrates that exposure to MEV is inducing
heritable epigenetic changes that manifest in the off-
spring. Although nicotine-containing e-vapour has been
shown to induce less hypermethylation than non-nicotine
containing e-vapour, the profile of which genes are being
methylated or demethylated is not yet known. Therefore,
further investigation is necessary to elucidate where in the
genome the modifications are taking place and the roles
these genes play in pathophysiology before making a con-
gruent decision on the role of e-vapour with and without
nicotine plays in epigenetics and respiratory disease.
Nicotine concentrations in e-liquid in the EU are per-
mitted to be as high as 20mg/ml; although, some samples
exceed that limit [121] leaving users susceptible to higher
nicotine exposure than anticipated. Studies on indoor air
quality have detected increased levels of nicotine and car-
cinogenic nitrosamines, such as N-nitrosonornicotine
(NNN) and nicotine-derived nitrosamine ketone (NNK)
in the atmosphere after e-cigarette use [131]. Serum cotin-
ine levels measured in non-smoking and non-vaping indi-
viduals exposed to environmental e-vapour found elevated
cotinine levels that equated to ETS exposure and persisted
at the same rate as ETS [61, 132], suggesting that
e-vapour remains in the atmosphere in a similar fashion
to ETS. Further, nicotine remaining in the indoor environ-
ment can react with oxidant gases in the atmosphere to
form added levels of NNN and NNK [133]. Nitrosamines
have been shown to methylate DNA and induce methyla-
tion DNA damage [134], which is a mechanism believed
to be behind their carcinogenicity [135, 136].
Studies have shown that foetal nicotine levels equate
to those in the mother [137] with nicotine capable of ac-
cumulating in the respiratory tract in the foetus [42].
Animal models of nicotine-only exposure show that off-
spring exhibit increased smooth muscle and collagen
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bulk in the airway, and augmented airway hyperreactivity
[138–140]. Altered lung development was shown to per-
sist in second-generation offspring not exposed to nico-
tine [141]. A murine model of nicotine exposure showed
that perinatal nicotine exposure altered DNA methyla-
tion and histone modification in the lung and gonads of
offspring and induced asthma-like changes that persisted
into the third generation of offspring [142], thereby
demonstrating functional respiratory and epigenetic ef-
fects induced by maternal nicotine exposure, together
with direct epigenetic changes to the germline. Corrob-
orating with these changes was a decrease in mRNA and
protein expression of peroxisome proliferator-activated
receptor γ (PPARγ) which plays an essential role in lung
development and repair [142–144]. Interestingly, when
Rosiglitazone, a known PPARγ agonist, was administered
in concert with nicotine to pregnant dams, asthma-like
changes and H3 acetylation induced by nicotine expos-
ure was prevented whilst nicotine induced global H4
acetylation and DNA methylation persisted [145], fur-
ther reinforcing the significance of PPARγ’s role in
healthy lung development. These seemingly paradoxical
effects of nicotine in e-liquids compared to those de-
scribed earlier in relation to cigarette smoking may re-
late to the dose and duration of exposure and to its
well-known anti-inflammatory effects [146].
The future of epigenetic therapeutics
The established role of epigenetics in pathophysiology
naturally implores exploring its therapeutic potential.
Using 5-azacytidine to inhibit DNMT1 in a murine
model of asthma augmented numbers of Treg cells and
effectively reduced airway inflammation [147]. The
pan-HDAC inhibitor, Trichostatin-A, has similarly
shown efficacy in asthma models [148], as has the allo-
steric activator of SIRT1, SRT1720 [149]. Targeting
HDAC classes 1–3 with MS-275 abrogated neutrophil
infiltration of the lungs and expression of proinflamma-
tory cytokines KC, IL-6 and IL-1β [150]. An in vitro
model of asthma using human airway smooth muscle
cells attenuated TGF-β-induced proliferation and
pro-inflammatory cytokine production with bromodo-
main inhibitors JQ1(+) and I-BET762 [151]. Using inhib-
itors to target proteins and enzymes active in epigenetic
modulation are useful tools in demonstrating the effect
of certain classes of epigenetic changes. However, due to
the nature of their targets, it is difficult to determine the
complete extent of which genes are within the purview
of the inhibitors.
To overcome this impediment, epigenetic therapeutics
may focus on the use of DNA targeting systems capable of
binding to genes of interest in a directed manner. The
three most well-understood DNA targeting systems are
zinc finger proteins (ZFPs), transcriptional-activator-like
effectors (TALEs), and clustered regularly interspaced short
palindromic repeats (CRISPR) and CRISPR-associated pro-
tein 9 (Cas9, 152); the latter of which being the most recent
advance in the field and most efficient as it is less cumber-
some than ZFPs and TALEs [152]. A study of SPDEF—a
regulator of mucus production in COPD known to be
hypomethylated [153]—in human lung epithelial cells ef-
fectively used ZFPs and CRISPR/dCas to attenuate
mucus-related gene expression and reduce mucus produc-
tion by silencing SPDEF [154]. Therein demonstrating that
targeted silencing of genes using epigenetic editing can re-
verse disease pathologies in vitro.
Conclusion
The evidence summarised in this review demonstrates
that maternal use of tobacco cigarettes and e-cigarettes
and exposure to environmental tobacco smoke induces
epigenetic changes in the offspring. These changes have
been demonstrated to contribute to disease pathology
and be passed down to further generations independent
of exposure. The all-encompassing nature of epigenetic
modifications implores research to consider using cell
types specifically implicated in disease pathologies, as
findings across differing cell types may obfuscate patho-
logical epigenetic differences with inherent epigenetic
differences dictating cell phenotype. Further, it is im-
perative to continue exploring intergenerational effects
of maternal e-cigarette use and exposure using animal
models on DNA methylation at specific genomic regions
and specific chromatin modifications to relate the
changes being induced to genes implicated in disease
pathology, thereby elucidating targets for the use of ad-
vanced DNA targeting systems in therapy. Finally, it is
recommended that further longitudinal studies on the
impacts of e-cigarettes are carried out, thereby allowing
us to distinguish between epigenetic modifications that
are biomarkers of exposure, such as the aforementioned
CYP1A1 and AHRR versus those that are likely to medi-
ate airway disease susceptibility.
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